This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown-Elliott, B. A.
Right arrow Articles by Wallace, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown-Elliott, B. A.
Right arrow Articles by Wallace, R. J., Jr.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1736-1738, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1736-1738.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Linezolid against Slowly Growing Nontuberculous Mycobacteria

Barbara A. Brown-Elliott,* Christopher J. Crist, Linda B. Mann, Rebecca W. Wilson, and Richard J. Wallace Jr.

Department of Microbiology, The University of Texas Health Center, Tyler, Texas

Received 2 December 2002/ Returned for modification 13 January 2003/ Accepted 29 January 2003

MICs of linezolid in broth microdilutions were tested against 341 slowly growing nontuberculous mycobacteria (NTM) belonging to 15 species. The proposed linezolid susceptibility MICs for all Mycobacterium marinum, Mycobacterium szulgai, Mycobacterium kansasii, Mycobacterium malmoense, and Mycobacterium xenopi isolates and for 90% of Mycobacterium gordonae and Mycobacterium triplex isolates were <=8 µg/ml. Linezolid has excellent therapeutic potential against most species of NTM.

* Corresponding author. Mailing address: University of Texas Health Center, Department of Microbiology, 11937 US Hwy. 271, Tyler, TX 75708. Phone: (903) 877-7685. Fax: (903) 877-7652. E-mail: barbara.elliott{at}uthct.edu.

Antimicrobial Agents and Chemotherapy, May 2003, p. 1736-1738, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1736-1738.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Condos, R., Hadgiangelis, N., Leibert, E., Jacquette, G., Harkin, T., Rom, W. N. (2008). Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis. Chest 134: 187-192 [Abstract] [Full Text]  
  • Strobel, S., Belpedio, D., Sharrer, E., Pepe, L., McClellan, S. (2008). Unusual Infection in the Foot of a Barefoot Gardener. J. Am. Podiatr. Med. Assoc. 98: 311-313 [Abstract] [Full Text]  
  • Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C. F., Wallace, R. J. Jr., Winthrop, K., on behalf of the ATS Mycobacterial Diseases Subcom, (2007). An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. 175: 367-416 [Full Text]  
  • Vera-Cabrera, L., Brown-Elliott, B. A., Wallace, R. J. Jr., Ocampo-Candiani, J., Welsh, O., Choi, S. H., Molina-Torres, C. A. (2006). In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria. Antimicrob. Agents Chemother. 50: 4027-4029 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Fortun, J., Martin-Davila, P., Navas, E., Perez-Elias, M. J., Cobo, J., Tato, M., De la Pedrosa, E. G.-G., Gomez-Mampaso, E., Moreno, S. (2005). Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56: 180-185 [Abstract] [Full Text]  
  • Liao, C.-H., Tseng, S.-P., Fang, C.-T., Teng, L.-J., Hsueh, P.-R. (2005). First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan. J Antimicrob Chemother 55: 598-599 [Full Text]  
  • Alcaide, F., Calatayud, L., Santin, M., Martin, R. (2004). Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against Mycobacterium kansasii. Antimicrob. Agents Chemother. 48: 4562-4565 [Abstract] [Full Text]  
  • Spellberg, B., Yoo, T., Bayer, A. S. (2004). Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 54: 832-835 [Abstract] [Full Text]  
  • Turenne, C. Y., Cook, V. J., Burdz, T. V., Pauls, R. J., Thibert, L., Wolfe, J. N., Kabani, A. (2004). Mycobacterium parascrofulaceum sp. nov., novel slowly growing, scotochromogenic clinical isolates related to Mycobacterium simiae. Int. J. Syst. Evol. Microbiol. 54: 1543-1551 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»